[A case of oral squamous cell carcinoma responding to S-1].
A 76-year-old patient with oral squamous cell carcinoma was treated by chemotherapy with S-1. S-1 (100 mg/body/day) was orally administered for 4 weeks followed by a 2-week rest period as one course. The primary lesion markedly decreased at 7 days after the beginning of S-1 treatment, and disappeared after one course of S-1. After two courses, the primary lesion was assessed to show a complete response (CR),and no tumor cells were identified as a result of biopsy. In addition, the value of tumor marker SCC decreased from 2.13 ng/mL before treatment to 0.68 ng/mL after two courses of S-1. Although the patient is still taking UFT, she is well with no signs of recurrence 50 months from the initial treatment.
Harada
Koji
K
Department of Therapeutic Regulation for Oral Tumors, Graduate School of Health and Bioscience, Tokushima University.
Tamatani
Tetsuya
T
Bando
Takashi
T
Yoshida
Hideo
H
D000284:Administration, Oral; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D009062:Mouth Neoplasms / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D015843:Serpins / Q000097:blood; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D004338:Drug Combinations; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid